Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.3%

122 terminated/withdrawn out of 991 trials

Success Rate

82.7%

-3.8% vs industry average

Late-Stage Pipeline

13%

125 trials in Phase 3/4

Results Transparency

45%

260 of 583 completed trials have results

Key Signals

178 recruiting260 with results95 terminated27 withdrawn

Enrollment Performance

Analytics

N/A

443(57.5%)

Phase 2

122(15.8%)

Phase 4

88(11.4%)

Phase 1

66(8.6%)

Phase 3

37(4.8%)

Early Phase 1

15(1.9%)

771Total

N/A(443)

Phase 2(122)

Phase 4(88)

Phase 1(66)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (991)

Showing 20 of 991 trials

NCT04856059Not ApplicableRecruiting

Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI

Role: collaborator

NCT04983875Not ApplicableActive Not Recruiting

Mammography and Breast Arterial Calcification: An Information-Sharing Trial

Role: lead

NCT05911568Recruiting

Treatment With Endovascular Intervention for STroke Patients With Existing Disability

Role: collaborator

NCT06619327Not ApplicableRecruiting

Resilient Together for Dementia (RT-D)

Role: lead

NCT03144765Not ApplicableActive Not Recruiting

Multicenter Phase II Study of Transanal TME (taTME)

Role: lead

NCT04334707Recruiting

Kidney Precision Medicine Project

Role: lead

NCT05095207Phase 1Recruiting

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Role: lead

NCT03718910Completed

DDX3X Syndrome -The Seaver Autism Center for Research and Treatment is Characterizing DDX3X-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

Role: lead

NCT07194187Not ApplicableNot Yet Recruiting

High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction

Role: lead

NCT01706939Phase 3Active Not Recruiting

The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer

Role: lead

NCT02055248Completed

Study on Moebius Syndrome and Congenital Facial Weakness Disorders

Role: collaborator

NCT06503614Phase 2Recruiting

A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Role: collaborator

NCT06398847Not ApplicableRecruiting

Virtual Reality (VR) Self-Hypnosis Software

Role: lead

NCT02945631Not ApplicableActive Not Recruiting

Quarterback 2b - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer

Role: lead

NCT07508488Phase 2Not Yet Recruiting

Deucravacitinib in the Treatment of Cicatricial Alopecias

Role: lead

NCT06092216Phase 2Terminated

Spesolimab in Pyoderma Gangrenosum

Role: lead

NCT06259097Phase 3Recruiting

Different Medications to Induce Labor

Role: lead

NCT04615988Recruiting

Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors

Role: lead

NCT07222501Active Not Recruiting

NIOSH R21 WTC Asthma

Role: lead

NCT07493317Phase 2Recruiting

Neutralizing Interleukin (IL)-6

Role: lead